Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial

Part of paid clinical trials in Buffalo, New York.

Sponsor
Roswell Park Cancer Institute
Study ID
NCT06563388
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
1 Year - N/A
Healthy Volunteers
Not accepted

Interventions

  • Stereotactic Ablative Radiotherapy — PROCEDURE
    Radiation therapy begins after 3 months of Standard of care
  • Best Practice — OTHER
    Receive standard of care therapy

Study Details

This protocol is comprised of three unblinded, randomized, single-center studies to evaluate the impact of immediate versus three-month delayed comprehensive ablative treatment on survival in newly diagnosed metastatic patients with lung (Trial 1), colorectal (Trial 2), and prostate (Trial 3) cancers

Key Dates

Start date
Sep 18, 2024
Status verified
Feb 2026
Primary completion
Sep 18, 2032
Completion
Sep 18, 2032

Study Design

Enrollment
800 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Standard Therapy followed by SABR - Trial 1-3 Arm 1
  • Experimental: SABR plus Standard therapy - Trial 1-3 Arm 2
  • Experimental: Trial 4 - Immediate SABR plus standard of care

Primary Outcome Measure

Overall Survival - Trial 1 and 2 [ Time Frame: UP to 5 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Roswell Park Comprehensive Cancer CenterBuffaloNew York14263
[email protected]
877-275-7724

Find similar trials in Buffalo, NY

By condition
Lung cancerProstate cancer
By specialty
OncologyLung oncologyLung diseaseProstate oncologyMen's healthUrology
By research site
Roswell Park Comprehensive Cancer Center· Buffalo, NY

Related Studies